Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Primate cell – per se
Reexamination Certificate
2001-11-09
2009-08-18
Burkhart, Michael (Department: 1633)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Primate cell, per se
C435S456000, C435S320100
Reexamination Certificate
active
07575924
ABSTRACT:
The present invention provides HIV-derived lentivectors which are safe, highly efficient, and very potent for expressing transgenes for human gene therapy, especially, in human hematopoietic progenitor cells as well as in all other blood cell derivatives. The lentiviral vectors comprise a self-inactivating configuration for biosaftey and promoters such as the EF1α promoter as one example. Additional promoters are also described. The vectors can also comprise additional transcription enhancing elements such as the wood chuck hepatitis virus post-transcriptional regulatory element. These vectors therefore provide useful tools for genetic treatments such as inherited and acquired lympho-hematological disorders, gene-therapies for cancers especially the hematological cancers, as well as for the study of hematopoiesis via lentivector-mediated modification of human HSCs.
REFERENCES:
patent: 4682195 (1987-07-01), Yilmaz
patent: 4683202 (1987-07-01), Mullis
patent: 5466468 (1995-11-01), Schneider et al.
patent: 5645897 (1997-07-01), Andra
patent: 5686279 (1997-11-01), Finer et al.
patent: 5705629 (1998-01-01), Bhongle
patent: 5846225 (1998-12-01), Rosengart et al.
patent: 5846233 (1998-12-01), Lilley et al.
patent: 5925565 (1999-07-01), Berlioz et al.
patent: 5928906 (1999-07-01), Koster et al.
patent: 5935819 (1999-08-01), Eichner et al.
patent: 5994136 (1999-11-01), Naldini et al.
patent: 6013516 (2000-01-01), Verma et al.
patent: 6017758 (2000-01-01), Haselton, III et al.
patent: 6084063 (2000-07-01), Vonakis et al.
patent: 6096538 (2000-08-01), Kingsman et al.
patent: 6136597 (2000-10-01), Hope et al.
patent: 6165782 (2000-12-01), Naldini et al.
patent: 6168916 (2001-01-01), Kingsman et al.
patent: 6207455 (2001-03-01), Chang
patent: 6218181 (2001-04-01), Verma et al.
patent: 6218186 (2001-04-01), Choi et al.
patent: 6235522 (2001-05-01), Kingsman et al.
patent: 6242258 (2001-06-01), Haselton, III et al.
patent: 6271359 (2001-08-01), Norris et al.
patent: 6277633 (2001-08-01), Olsen
patent: 6312682 (2001-11-01), Kingsman et al.
patent: 6312683 (2001-11-01), Kingsman et al.
patent: 6428953 (2002-08-01), Naldini et al.
patent: 6440730 (2002-08-01), Von Laer et al.
patent: 2001/0009772 (2001-07-01), Verma et al.
patent: 2002/0034393 (2002-03-01), Mitrophanous et al.
patent: 2002/0034502 (2002-03-01), Kingsman et al.
patent: 2002/0123471 (2002-09-01), Uberla
patent: WO 99/04026 (1999-01-01), None
patent: WO 00/15819 (2000-03-01), None
patent: WO 00/55335 (2000-09-01), None
patent: WO 01/27304 (2001-04-01), None
patent: WO 01/34843 (2001-05-01), None
patent: WO 01/44481 (2001-06-01), None
patent: WO 01/92506 (2001-12-01), None
patent: WO 02/087341 (2002-11-01), None
Deisseroth Clinical Cancer Research 5: 1607-1609, 1999.
Juengst BMJ, 326:1410-11, 2003.
Anderson WF, Nature 392:25-30, 1998.
Chang et al Gene Therapy 6;715-728, 1999.
Akkina et al., “High-efficiency gene transfer into CD34+ cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G,” J. Virol., 70:2581-2585, 1996.
An et al., “Marking and gene expression by a lentivirus vector in transplanted human and nonhuman primate CD34(+) cells,”J. Virol., 74:1286-1295, 2000.
Arrighi et al., “Long-term culture of human CD34(+) progenitors with FLT3-ligand, thrombopoietin, and stem cell factor induces extensive amplification of a CD34(−)CD14(−) and CD34(−)CD14(+) dendritic cell precursor,”Blood, 93:2244-2252, 1999.
Berkhout et al., “Tat Trans-activates the Human Immunodeficiency Virus Through a Nascent RNA Target,”Cell, 59:273-282, 1989.
Bhatia et al., “Quantitative analysis reveals expansion of human hematopoietic repopulating cells after short-term ex vivo culture,”J. Exp. Med., 186:619-624, 1997.
Bömer et al., “Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector,”J. Virol., 71:6441-6649, 1997.
Brown et al., “Efficient polyadenylation within the human immunodeficiency virus type 1 long terminal repeat requires flanking U3-specific sequences,”J. Virol., 65:3440-3343, 1991.
Carbonelli et al. “A plasmid vector for isolation of strong promoters inE. coli,” FEMS Microbiol Lett.177(1):75-82, 1999.
Case et al., “Stable transduction of quiescent CD34(+)CD38(−) human hematopoietic cells by HIV-1 based lentiviral vectors,”Proc. Natl. Acad. Sci. USA, 96:2988-2993, 1999.
Chandler et al., “RNA splicing specificity determined by the coordinated action of RNA recognition motifs in SR proteins,”Proc Natl Acad Sci U S A. 94(8):3596-3601, 1997.
Cherrington and Ganem, “Regulation of polyadenylation in human immunodeficiency virus (HIV): contributions of promoter proximity and upstream sequences,”Embo. J., 11:1513-1524, 1992.
Cocea, “Duplication of a region in the multiple cloning site of a plasmid vector to enhance cloning-mediated addition of restriction sites to a DNA fragment,”Biotechniques, 23:814-816, 1997.
Corbeau, et al., “Efficient gene transfer by a human immunodeficiency virus type 1 (HIV-1)-derived vector utilizing a stable HIV packaging cell line,”PNAS U.S.A., 93(24):14070-14075, 1996.
Dao et al., “Adhesion to fibronectin maintains regenerative capacity during ex vivo, culture and transduction of human hematopoietic stem and progenitor cells,”Blood, 92:4612-4621, 1998.
Dao et al., “FLT3 ligand preserves the ability of human CD34+ progenitors to sustain long-term hematopoiesis in immune-deficient mice after ex vivo retroviral-mediated transduction,”Blood, 89:446-456, 1997.
DeZazzo et al., “Involvement of long terminal repeat U3 sequences overlapping the transcription control region in human immunodeficiency virus type 1 mRNA 3′ end formation,”Mol. Cell. Biol., 11:1624-1630, 1991.
Donello et al., “Woodchuck hepatitis virus contains a tripartite posttranscriptional regulatory element,”J. Virol., 72:5085-5092, 1998.
Dorrell et al., “Expansion of human cord blood CD34(+)CD38(−) cells in ex vivo culture during retroviral transduction without a corresponding increase in SCID repopulating cell (SRC) frequency: dissociation of SRC phenotype and function,”Blood, 95:102-110, 2000.
Dull et al., “A third-generation lentivirus vector with a conditional packaging system,”J. Virology, 72:8463-8471, 1998.
Feng and Holland, “HIV-I Tat Trans-Activation Requires the Loop Sequence Within Tar,”Nature, 334(6178):165-167, 1988.
Gilmartin et al., “Activation of HIV-1 pre-mRNA 3′ processing in vitro requires both an upstream element and TAR,”Embo. J., 11:4419-4428, 1992.
Gossen and Bujard, “Tight control of gene expression in mammalian cells by tetracycline-responsive promoters,”Proc. Natl. Acad. Sci., 89:5547-5551, 1992.
Kafri et al,. “Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors,”Nature Genetics, 17:314-317, 1997.
Kohn et al., “Toward gene therapy for Gaucher disease,”Hum. Gene Ther., 2:101-105, 1991.
Levenson et al., “Internal ribosomal entry site-containing retroviral vectors with green fluorescent protein and drug resistance markers,”Human Gene Therapy, 9:1233-1236, 1998.
Lewis and Emerman, “Passage through mitosis is required for oncorertoviruses but not for the human immunodeficiency virus,”J. Virology, 68:510-516, 1994.
Marthas et al. “Viral determinants of simian immunodeficiency virus (SIV) virulence in Rhesus Macaques assessed by using attentuated and pathogenic molecular clones of SIVmac,”J. Virol., 67:6047-6955, 1993.
Mazurier et al., “Rapid analysis and efficient selection of human transduced primitive hematopoietic cells using the humanized S65T green fluorescent protein,”Gene Ther., 5:556-562, 1998.
Miyoshi et al., “Transduction of human C
Salmon Patrick
Trono Didier
Burkhart Michael
Fulbright & Jaworski LLP
Research Development Foundation
LandOfFree
Methods and compositions relating to improved lentiviral... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions relating to improved lentiviral..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions relating to improved lentiviral... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4112074